Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
September 07 2022 - 4:00PM
Daix (France), Long Island
City (New York, United States), September 7, 2022 –
Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a
clinical-stage biopharmaceutical company focused on the development
of oral small molecule therapies for the treatment of patients with
non-alcoholic steatohepatitis (NASH) and other diseases with
significant unmet medical needs, today announced that its
management team will host a webcast to present the Company’s 2022
half-year financial results on Thursday, September 22, 2022.
Inventiva’s 2022
half-year financial results will be published on Wednesday,
September 21, 2022 at 4:00 pm (New York), 10:00 pm (Paris).
Frédéric Cren, Chairman, CEO and cofounder of
Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of
Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and
Michael Cooreman, Chief Medical Officer of Inventiva, will hold a
conference call in English, followed by a Q&A
session, on Thursday, September 22, 2022 at
8:00 am (New York), 2:00 pm (Paris).
The conference call and the slides of the
presentation will be webcast live at:
https://edge.media-server.com/mmc/p/v5uzhkr8 and also available on
Inventiva’s onwards in the “Investors” – “Financial results”
section.
In order to receive the conference
access information necessary to join the conference call, it is
required to register in advance using the following link:
https://register.vevent.com/register/BI3a0c8ee6960a4b7a9db4026550ff3f51.In
the 10 minutes prior to the call start time, participants will need
to use the conference access information provided in the e-mail
received at the point of registering (dial-in number and access
code).
A replay of the conference call and the
presentation will be available after the event at:
http://inventivapharma.com/investors/financial-results-presentations/.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with NASH and
other diseases with significant unmet medical need. The Company
benefits from a strong expertise and experience in the domain of
compounds targeting nuclear receptors, transcription factors and
epigenetic modulation. Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with NASH, a common and
progressive chronic liver disease for which there are currently no
approved therapies.
The Company has established a strategic
collaboration with AbbVie in the area of autoimmune diseases that
resulted in the discovery of the drug candidate cedirogant
(ABBV-157), an oral RORγ inverse agonist which is being evaluated
in a Phase IIb clinical trial, led by AbbVie, in adult patients
with moderate to severe chronic plaque psoriasis. Inventiva’s
pipeline also includes odiparcil, a drug candidate for the
treatment of adult mucopolysaccharidoses (MPS) VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is in the
process of selecting an oncology development candidate for its
Hippo signalling pathway program.
The Company has a scientific team of
approximately 80 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com.
Contacts
InventivaPascaline ClercVP of Global External
Affairs media@inventivapharma.com+1 240 620 9175 |
Brunswick GroupTristan Roquet Montegon / Aude
Lepreux / Matthieu BenoistMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke,
an ICR CompanyPatricia L. Bank Investor
relationspatti.bank@westwicke.com+1 415 513 1284 |
|
|
|
- Inventiva - PR - Webcast invitation H1 2022 - 07 09 2022 -
EN
Inventiva (EU:IVA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Aug 2023 to Aug 2024